Evidence map›Paper›PMID 40138016›Full record

ArticleMolecular biology reports2025

FGFR3 gene mutations screening in non-muscle invasive bladder cancer (NMIBC) in the Tunisian population.

Bilel Saidani, Nouha Setti Boubaker, Marouen Chakroun, Haroun Ayed, Meriem Ksontini, Zeineb Naimi, Khedija Meddeb, Ahmed Saadi, Soumaya Rammeh, Mohamed Riadh Ben Slama

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bilel Saidani *Urology Department, Charles Nicolle Hospital, Faculty of Medicine, Tunis El Manar University, Tunis, 1006, Tunisia.
Nouha Setti Boubaker *Theranostic Biomarkers LR23ES02, Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, 1006, Tunisia. nouha.setti@hotmail.fr.
Marouen ChakrounUrology Department, Charles Nicolle Hospital, Faculty of Medicine, Tunis El Manar University, Tunis, 1006, Tunisia.
Haroun AyedUrology Department, Charles Nicolle Hospital, Faculty of Medicine, Tunis El Manar University, Tunis, 1006, Tunisia.
Meriem KsontiniPathology Department, Charles Nicolle Hospital, Faculty of Medicine, University Tunis El Manar, Tunis, 1006, Tunisia.
Zeineb NaimiMedical Oncology Department, Salah Azaiez Institute, Faculty of Medicine, University Tunis El Manar, Tunis, 1006, Tunisia.
Khedija MeddebMedical Oncology Department, Salah Azaiez Institute, Faculty of Medicine, University Tunis El Manar, Tunis, 1006, Tunisia.
Ahmed SaadiUrology Department, Charles Nicolle Hospital, Faculty of Medicine, Tunis El Manar University, Tunis, 1006, Tunisia.
Soumaya RammehTheranostic Biomarkers LR23ES02, Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, 1006, Tunisia.
Mohamed Riadh Ben SlamaUrology Department, Charles Nicolle Hospital, Faculty of Medicine, Tunis El Manar University, Tunis, 1006, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMutations occurring in the Fibroblast Growth Factor Receptor (FGFR3) gene are thought to be associated with the incidence and prognosis of non-muscle invasive bladder tumors (NMIBC). Yet, their prognostic significance in the Tunisian population remains unclear. Herein, we aim to investigate their prognostic impact in NMIBC in terms of recurrence, progression, and survival. METHODS AND

resultsIt is a monocentric retrospective study including 42 NMIBC patients. DNA was isolated from formalin-fixed paraffin-embedded tissue samples. Polymerase Chain Reaction (PCR) followed by Sanger sequencing were performed for a targeted mutations' screening of the hot-spot regions of the FGFR3 gene (exons 7 and 15). Overall survival (OS) and disease-specific survival (DSS) were estimated by the Kaplan-Meier method and the corresponding curves were compared using log-rank test. Sequencing analysis revealed 15 different mutations in FGFR3 gene across 26 different tumors (68%). Among these, 9 are already reported mutations (S249C, P250R, P250S, H251Q, S249S, S249Y, S249A, T264T, Thr651) and, interestingly, 6 are new variants (P250A, H251L, A257S, P253P, I254V, R618S). FGFR3-mutated NMIBC and wild-type FGFR3 tumors were comparable in terms of clinical and endoscopic presentation. The presence of FGFR3 mutations was not statistically correlated to a decrease in OS and DSS. The main factors correlated with their presence were the solid appearance of the tumor (p = 0.04), the presence of tumor calcifications (p = 0.04), and tumor stage (p = 0.04).

conclusionFGFR3 mutations were common in our series. These variations seem to be a favorable prognostic factor for NMIBC in our population.

Indexed as

Receptor, Fibroblast Growth Factor, Type 3Urinary Bladder NeoplasmsAdultAgedAged, 80 and overFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMutationNeoplasm Recurrence, LocalNon-Muscle Invasive Bladder NeoplasmsPrognosisRetrospective StudiesTunisiaFGFR3 protein, humanReceptor, Fibroblast Growth Factor, Type 3Bladder cancerFGFR3Pathway enrichmentPrognosisProgressionRecurrence

Identifiers

PMID40138016

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.